Scientists from an initiative launched by the Parker Institute for Cancer Immunotherapy (PICI) and the Cancer Research Institute called the Tumor Neoantigen Selection Alliance (TESLA) have discovered parameters to better predict which neoantigens can stimulate a cancer-killing effect.
Taking over-the-counter probiotic supplements was associated with a 70 percent lower chance of response to cancer immunotherapy treatment with anti-PD-1 checkpoint inhibitors in melanoma patients, according to a preliminary study from the Parker Institute for Cancer Immunotherapy (PICI) and The University of Texas MD Anderson Cancer Center. The results are being presented April 2 at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta.
Combining immunotherapy with chemotherapy shrank tumors in 20 out of 24 patients with advanced pancreatic cancer, according to early phase 1b data being unveiled at AACR 2019 by Parker Institute for Cancer Immunotherapy (PICI) researchers at the University of Pennsylvania.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right